Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
TNGX affiliate submitted a Form 144 notifying an intended sale of 65,460 common shares on 05/01/2026 arising from an exercise of stock options for cash. The filing also reports multiple prior 10b5-1 sales by Adam Crystal totaling reported share lots and proceeds in early 2026.
Tango Therapeutics, Inc. Principal Accounting Officer Jessica Newcomb filed an initial ownership report showing she directly holds 67,321 shares of Common Stock, including 43,666 unvested restricted stock units. She also holds multiple stock options to buy Common Stock at exercise prices between $2.67 and $12.28, expiring between 2032 and 2036, many of which vest over four-year service-based schedules.
Tango Therapeutics, Inc. filed an initial Form 3 for Chief Financial Officer Matthew Gall. The filing identifies him as an officer but, in the provided data, shows no reportable transactions, derivative positions, or other holdings, indicating this is a baseline ownership statement rather than a trading disclosure.
Tango Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 4, 2026 at 9:00 a.m. Eastern Time. Investors will elect three Class II directors to terms ending in 2029, ratify PricewaterhouseCoopers LLP as auditor for 2026, and give an advisory vote on executive pay.
The proxy also highlights clinical progress, including positive 2025 Phase 1/2 monotherapy data for vopimetostat, initiation of combination studies in MTAP-deleted, RAS-mutant cancers, first dosing with brain-penetrant PRMT5 inhibitor TNG456, and a $225 million financing completed in October 2025. There were 144,242,271 common shares outstanding and entitled to vote as of April 7, 2026.
Tango Therapeutics, Inc. President of R&D Crystal Adam exercised stock options to acquire 38,460 shares of common stock at an exercise price of $5.20 per share, then sold 38,460 shares in an open-market transaction at $25.00 per share. Following the sale, she directly holds 112,622 common shares. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025.
Tango Therapeutics announced several leadership changes and equity awards to support its late-stage oncology pipeline. The board decided that Daniella Beckman will step down as Chief Financial Officer, principal accounting officer and principal financial officer, effective April 15, 2026.
Effective the same date, Matthew Gall becomes Chief Financial Officer and principal financial officer under an employment agreement that includes an option for 240,000 shares and 40,000 restricted stock units, subject to time-based vesting and continued employment. Jessica Newcomb is appointed principal accounting officer, while a related press release highlights additional senior hires in development operations and corporate strategy to help advance vopimetostat toward potential regulatory approval in pancreatic cancer.
Tango Therapeutics President of R&D Crystal Adam exercised stock options for 27,000 shares of common stock at an exercise price of $5.20 per share and, on the same day, sold 27,000 shares at a weighted-average price of $21.2029 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. After the sale, Adam directly holds 112,622 shares of Tango Therapeutics common stock.
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an option exercise and related stock sale. On March 25, 2026, she exercised stock options to acquire 12,000 shares of common stock at $5.20 per share, then sold 12,000 shares in open‑market transactions at a weighted‑average price of $20.11 per share.
These trades were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on October 27, 2025. After the transactions, she held 112,622 shares of common stock directly and 460,500 stock options, indicating the sale represents a relatively small portion of her overall position.
Tango Therapeutics received a Schedule 13G/A amendment from The Vanguard Group reporting 0 shares of Common Stock, representing 0% of the class. The filing states that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538; as a result, The Vanguard Group no longer reports beneficial ownership of those securities. The amendment is signed by Ashley Grim on March 27, 2026.